Advertisement

Topics

Heparin Lock Flush Solution, USP | Heparin Lock Flush [APP Pharmaceuticals, LLC] | BioPortfolio

12:11 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

FOR MAINTENANCE OF PATENCY OF INTRAVENOUS INJECTION DEVICES ONLY.

NOT FOR ANTICOAGULANT THERAPY.

DERIVED FROM PORCINE INTESTINAL MUCOSA.

PRESERVATIVE FREE.

Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans having anticoagulant properties. Although others may be present, the main sugars occurring in heparin are: (1) α-L-iduronic acid 2-sulfate, (2) 2-deoxy-2-sulfamino-α-D-glucose 6-sulfate, (3) ß-D-glucuronic acid, (4) 2-acetamido-2-deoxy-α-D-glucose and (5) α-L-iduronic acid.  These sugars are present in decreasing amounts, usually in the order (2)> (1)> (4)> (3)> (5), and are joined by glycosidic linkages, forming polymers of varying sizes.  Heparin is strongly acidic because of its content of covalently linked sulfate and carboxylic acid groups.  In heparin sodium, the acidic protons of the sulfate units are partially replaced by sodium ions.

Heparin Lock Flush Solution, USP is a sterile preparation of heparin sodium derived from porcine intestinal mucosa, standardized for anticoagulant activity, with sufficient sodium chloride to make it isotonic with blood.  The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram. 

Structure of Heparin Sodium (representative subunits):

 

Each mL contains: 10 USP Units Heparin sodium (porcine); 9 mg sodium chloride; Water for Injection q.s.  Sodium hydroxide and/or hydrochloric acid for pH adjustment (5.0-7.5).

Each mL contains: 100 USP Units Heparin sodium (porcine); 9 mg sodium chloride; Water for Injection q.s.  Sodium hydroxide and/or hydrochloric acid for pH adjustment (5.0-7.5).

Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo .  Heparin acts at multiple sites in the normal coagulation system.  Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin.  Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin.  Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.

Bleeding time is usually unaffected by heparin.  Clotting time is prolonged by full therapeutic doses of heparin; in most cases it is not measurably affected by low doses of heparin.  Loglinear plots of heparin plasma concentrations with time, for a wide range of dose levels, are linear, which suggests the absence of zero order processes.  Liver and the reticulo-endothelial system are the sites of biotransformation.  The biphasic elimination curve, a rapidly declining alpha phase (t= 10 minutes) and after the age of 40 a slower beta phase, indicates uptake in organs.  The absence of a relationship between anticoagulant half-life and concentration half-life may reflect factors such as protein binding of heparin.

Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastine times (APTTs) compared with patients under 60 years of age.

Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.

Heparin Lock Flush Solution, USP is intended to maintain patency of an indwelling venipuncture device designed for intermittent injection or infusion therapy or blood sampling.  Heparin lock flush solution may be used following initial placement of the device in the vein, after each injection of a medication or after withdrawal of blood for laboratory tests (see DOSAGE AND ADMINISTRATION ,   Maintenance of Patency of IV Devices for directions for use).

Heparin lock flush solution is not to be used for anticoagulant therapy.

Heparin sodium should NOT be used in patients with the following conditions: severe thrombocytopenia; an uncontrollable active bleeding state (see WARNINGS ), except when this is due to disseminated intravascular coagulation.

Heparin is not intended for intramuscular use.

Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations (see Adverse Reactions , Hypersensitivity).

Hemorrhage can occur at virtually any site in patients receiving heparin.  An unexplained fall in hematocrit, fall in blood pressure or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.

Heparin sodium should be used with extreme caution in infants and in patients with disease states in which there is increased danger of hemorrhage.  Some of the conditions in which increased danger of hemorrhage exists are:

Cardiovascular –Subacute bacterial endocarditis, severe hypertension.

Surgical –During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord or eye.

Hematologic –Conditions associated with increased bleeding tendencies, such as hemophilia, thrombocytopenia and some vascular purpuras.

Gastrointestinal –Ulcerative lesions and continuous tube drainage of the stomach or small intestine.

Other –Menstruation, liver disease with impaired hemostasis.

Thrombocytopenia has been reported to occur in patients receiving heparin with a reported incidence of 0 to 30%.  Platelet counts should be obtained at baseline.  Mild thrombocytopenia (count greater than 100,000/mm) may remain stable or reverse even if heparin is continued.  However, thrombocytopenia of any degree should be monitored closely.  If the count falls below 100,000/mmor if recurrent thrombosis develops (see Heparin-induced Thrombocytopenia and Heparin-induced Thrombocytopenia and Thrombosis), the heparin product should be discontinued and, if necessary, an alternative anticoagulant administered.

Heparin-induced Thrombocytopenia (HIT) is a serious antibody-mediated reaction resulting from irreversible aggregation of platelets.  HIT may progress to the development of venous and arterial thromboses, a condition referred to as Heparin-induced Thrombocytopenia and Thrombosis (HITT).  Thrombotic events may also be the initial presentation for HITT.  These serious thromboembolic events include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, mesenteric thrombosis, renal arterial thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death.  Thrombocytopenia of any degree should be monitored closely.  If the platelet count falls below 100,000/mm or if recurrent thrombosis develops, the heparin product should be promptly discontinued and alternative anticoagulants considered if patients require continued anticoagulation.

Heparin-induced Thrombocytopenia and Heparin-induced Thrombocytopenia and Thrombosis can occur up to several weeks after the discontinuation of heparin therapy.  Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT.

Preservative-Free Heparin Lock Flush Solution, USP should be used for maintaining the patency of intravenous injection devices in neonates.

In infants, the cumulative amounts of heparin received from the frequent administration of Heparin Lock Flush Solution, USP during a 24- hour period should be considered.

Precautions must be exercised when drugs which are incompatible with heparin are administered through an indwelling intravenous catheter containing Heparin Lock Flush Solution, USP (see DOSAGE AND ADMINISTRATION ,   Maintenance of Patency of IV Devices ).

See WARNINGS .

Increased Risk to Older Patients, Especially Women –A higher incidence of bleeding has been reported in patients, particularly women over 60 years of age.

Periodic platelet counts, hematocrits and tests for occult blood in stool are recommended during the entire course of heparin use (see DOSAGE AND ADMINISTRATION ).

Platelet Inhibitors –Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.

Other Interactions –Digitalis, tetracyclines, nicotine or antihistamines may partially counteract the anticoagulant action of heparin sodium.

No long-term studies in animals have been performed to evaluate the carcinogenic potential of heparin.  Also, no reproduction studies in animals have been performed concerning mutagenesis or impairment of fertility.

Teratogenic Effects: Pregnancy Category C –

Animal reproduction studies have not been conducted with heparin sodium.  It is also not known whether heparin sodium can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Heparin sodium should be given to a pregnant woman only if clearly needed.

Nonteratogenic Effects –Heparin does not cross the placental barrier.

Heparin is not excreted in human milk.

Safety and effectiveness in pediatric patients have not been established.  Not for use in neonates (see WARNINGS ).

A higher incidence of bleeding has been reported in patients over 60 years of age, especially women (see PRECAUTIONS, General and CLINICAL PHARMACOLOGY ).

Hemorrhage is the chief complication that may result from heparin use (see WARNINGS ).  An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug (see OVERDOSAGE ).

See WARNINGS .

Local irritation and erythema have been reported with the use of heparin lock flush solution.

Generalized hypersensitivity reactions have been reported, with chills, fever and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring more rarely.  Itching and burning, especially on the plantar side of the feet, may occur.

Thrombocytopenia has been reported to occur in patients receiving heparin, with a reported incidence of 0 to 30%.  While often mild and of no obvious clinical significance, such thrombocytopenia can be accompanied by severe thromboembolic complications such as skin necrosis, gangrene of the extremities that may lead to amputation, myocardial infarction, pulmonary embolism, stroke, and possibly death (see WARNINGS and PRECAUTIONS ).

Certain episodes of painful, ischemic and cyanosed limbs have in the past been attributed to allergic vasospastic reactions.  Whether these are in fact identical to the thrombocytopenia-associated complications remains to be determined.

Bleeding is the chief sign of heparin overdosage.  Nosebleeds, blood in urine or tarry stools may be noted as the first sign of bleeding.  Easy bruising or petechial formations may precede frank bleeding.

When clinical circumstances (bleeding) require reversal of heparinization, protamine sulfate (1% solution) by slow infusion will neutralize heparin sodium.   No more than 50 mg should be administered, very slowly, in any 10 minute period.  Each mg of protamine sulfate neutralizes approximately 100 USP heparin units.  The amount of protamine required decreases over time as heparin is metabolized.  Although metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about 1/2 hour after intravenous injection.

Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions.  Because fatal reactions often resembling anaphylaxis have been reported, the drug should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available.

For additional information consult the labeling of Protamine Sulfate Injection, USP products.

Parental drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.  Slight discoloration does not alter potency.

Heparin Lock Flush Solution, USP is not recommended for use in the neonate (see WARNINGS ).

To prevent clot formation in a heparin lock set or central venous catheter following its proper insertion, Heparin Lock Flush Solution, USP is injected via the injection hub in a quantity sufficient to fill the entire device.  This solution should be replaced each time the device is used.  Aspirate before administering any solution via the device in order to confirm patency and location of needle or catheter tip.  If the drug to be administered is incompatible with heparin, the entire device should be flushed with normal saline before and after the medication is administered; following the second saline flush, the heparin lock flush solution may be reinstilled into the device.  The device manufacturer’s instructions should be consulted for specifics concerning its use.  Usually this dilute heparin solution will maintain anticoagulation within the device for up to 4 hours.

NOTE:   Since repeated injections of small doses of heparin can alter tests for activated partial thromboplastin time (APTT), a baseline value for APTT should be obtained prior to insertion of a heparin lock set.

Heparin lock flush solution may also be used after each withdrawal of blood for laboratory tests.  When heparin would interfere with or alter the results of blood tests, the heparin solution should be cleared from the device by aspirating and discarding it before withdrawing the blood sample.

Unused portion of the vial should be discarded.

Use only if solution is clear and seal intact.

Product No. NDC No.  

504901 63323-549-01 Heparin Lock Flush Solution, USP, Preservative Free, 100 USP Units/mL, 1 mL fill, in a 3 mL flip-top, single dose plastic vial, in packages of 25.
505701 63323-557-01 Heparin Lock Flush Solution, USP, Preservative Free, 10 USP Units/mL, 1 mL fill, in a 3 mL flip-top, single dose plastic vial, in packages of 25.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

For Product Inquiry: 1-800-551-7176

451198A

Issued: July 2010

PACKAGE LABEL - PRINCIPAL DISPLAY - Heparin Lock Flush Solution 1 mL Single Dose Vial Label

NDC 63323-549-01

504901

Heparin Lock Flush Solution, USP

100 USP Units/mL

(Derived from Porcine Intestinal Mucosa)

Preservative Free                 Rx only

1 mL Single Dose Vial

PACKAGE LABEL - PRINCIPAL DISPLAY - Heparin Lock Flush Solution 1 mL Single Dose Vial Tray Label

NDC 63323-549-01

504901

Heparin Lock Flush Solution, USP

100 USP Units/mL

(Derived from Porcine Intestinal Mucosa)

1 mL Single Dose Vial

Rx only

 

PACKAGE LABEL - PRINCIPAL DISPLAY - Heparin Lock Flush Solution 1 mL Single Dose Vial

NDC 63323-557-01

505701

Heparin Lock Flush Solution, USP

10 USP Units/mL

(Derived from Porcine Intestinal Mucosa)

Preservative Free                 Rx only

1 mL Single Dose Vial

PACKAGE LABEL - PRINCIPAL DISPLAY - Heparin Lock Flush Solution 1 mL Single Dose Vial Tray Label

NDC 63323-557-01

505701

Heparin Lock Flush Solution, USP

10 USP Units/mL

(Derived from Porcine Intestinal Mucosa)

1 mL Single Dose Vial

Rx only

Manufacturer

APP Pharmaceuticals, LLC

Active Ingredients

Source

Drugs and Medications [180 Associated Drugs and Medications listed on BioPortfolio]

Heparin sodium [cantrell drug company]

Heparin Sodium 25,000 USP Units Added to 0.45% Sodium Chloride 250 mL Bag

Heparin sodium [general injectables & vaccines, inc]

Heparin Sodium Injection, USPDerived from Porcine Intestinal MucosaPreserved with Benzyl AlcoholRx only

Heparin sodium [hospira, inc.]

These highlights do not include all the information needed to use HEPARIN SODIUM INJECTION safely and effectively. See full prescribing information for HEPARIN SODIUM INJECTION. HEPARIN SODIUM INJECTI...

Heparin sodium [cantrell drug company]

Heparin Sodium 25,000 USP Units Added to 5% Dextrose 500 mL Bag

Heparin sodium [cantrell drug company]

Heparin Sodium 25,000 USP Units Added to 5% Dextrose 250 mL Bag

Clinical Trials [496 Associated Clinical Trials listed on BioPortfolio]

Pediatric Ethanol Lock Therapy

This study is a double-blind crossover design to compare prophylaxis with ethanol lock therapy versus placebo lock therapy (heparin). The primary outcome measure will be the number of cath...

Biological and Clinical Measurements Following Systemic Leakage When a Citrate or Heparin Lock is Used

In the VERROUREA study, there were two cases of an abnormal increase in TCA. In theory no leakage of the lock into the bloodstream should have been seen. Lock leakage could have particular...

Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?

Addition of Heparin to the Catheter Lock Solution (CLS): Taurolock-TM will improve the vascular patency compared to Taurolock-TM alone , in hemodialysis patients with Tunneled Cuffed Cath...

Ethanol Locks for the Treatment of Central Venous Line Infections

Ethanol Locks as an Adjunct Treatment for Central Venous Line Infections Purpose To evaluate the effectiveness of a 70% ethanol lock solution when used as an adjunct therapy with antibiot...

Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia

Children with cancer need a long term tunnelled central venous catheter (TCVC) for the entire duration of their treatment. TCVCs are locked with heparin when not in use. The most frequent...

PubMed Articles [313 Associated PubMed Articles listed on BioPortfolio]

Field testing of a prototype mechanical dry toilet flush.

A prototype of a non-fluid based mechanical toilet flush was tested in a semi-public, institutional setting and in selected peri-urban households in eThekwini municipality, Republic of South Africa. T...

Dimeric FcγR ectodomains detect pathogenic platelet factor 4-heparin antibodies in heparin induced thromobocytopenia.

Heparin induced thrombocytopenia (HIT) is a major and potentially fatal consequence of antibodies produced against platelet factor 4 (PF4)-heparin complexes following heparin exposure. Not all anti-PF...

Evaluation of prophylactic heparin dosage strategies and risk factors for venous thromboembolism in the critically ill patient.

Venous thromboembolism (VTE) occurs frequently in critically ill patients without heparin prophylaxis. Although heparin prevents VTE, VTEs occur frequently despite prophylaxis. Higher heparin dosage m...

Comparison of Continuation of Low-Molecular-Weight Heparin versus Switching to Unfractionated Heparin in the Peripartum.

 This study aimed to determine whether switching from low-molecular-weight heparin (LMWH) to unfractionated heparin (UFH) or its continuation in the peripartum affected anesthesia choice or bleeding...

Heparin during endovascular stroke treatment seems safe Heparin during endovascular stroke treatment does not ameliorate clinical outcome and is associated with lower chance of reperfusion.

the effect of intravenous heparin during mechanical thrombectomy for acute ischemic stroke is not clear. We aimed to study efficacy and safety of heparin use during endovascular stroke treatment in a ...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Assays
An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record